Notably, however, mutations in the DDR system, including BRCA1 and BRCA2, but also ATM and PALB2, are emerging biologic targets for therapy in advanced pancreatic cancer [35]. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.